Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
Combined Aerobic and Resistance Training Best Improves Beta-Cell Function in Type 2 Diabetes
An RCT finds combined aerobic and resistance training improves modelled insulin secretion and glucose effectiveness more than either alone in men with type 2 diabetes. PICO summary and commentary.
Curcumin Supplementation Reduces Liver Fat and Inflammation in Obese Type 2 Diabetes: 12-Month RCT
A 12-month RCT finds daily curcumin reduces liver fat, stiffness, and HbA1c and improves inflammatory and antioxidant markers in obese type 2 diabetes with fatty liver. PICO summary and commentary.
Probiotic Bifidobacterium animalis Improves Glycemic Control in Type 2 Diabetes: Crossover RCT
A crossover RCT finds a specific Bifidobacterium animalis probiotic blunts the rise in glucose and insulin resistance and raises immunoglobulins in type 2 diabetes, with modest adjunctive benefit. PICO summary and commentary.
Semaglutide Outperforms Alternative Therapies in Real-World Pragmatic Trial of Type 2 Diabetes
A 2-year pragmatic open-label trial finds once-weekly semaglutide modestly outperforms physician-chosen alternatives on HbA1c targets, with a year-1 weight advantage that fades by year 2. PICO summary and commentary.
Sitagliptin Preserves Hip Bone Density in Women with Type 2 Diabetes: SLowDOWN Trial
A 52-week phase III RCT finds sitagliptin preserves hip bone density in women with type 2 diabetes, which declines on placebo, but with no effect at other sites. PICO summary and commentary.
How does an interdisciplinary care model with family support impact blood pressure and glucose control in patients with hypertension and diabetes?
An RCT finds an interdisciplinary care model with family empowerment improves blood pressure, glucose, and psychosocial outcomes in comorbid hypertension and diabetes. PICO summary and commentary.
“How do metformin and ezetimibe affect gene expression and health in MAFLD patients with type 2 diabetes?”
An RCT finds adding ezetimibe to metformin raises PPAR-gamma and adiponectin expression and improves insulin resistance in diabetic fatty liver disease, though endpoints are surrogate. PICO summary and commentary.
How do fixed-dose and separate enavogliflozin/gemigliptin combinations compare on pharmacokinetics and safety, and does food affect enavogliflozin in healthy Korean volunteers?
A phase-1 crossover study in healthy Korean volunteers found a fixed-dose enavogliflozin/gemigliptin combination pharmacokinetically equivalent to the separate tablets, with food delaying only the time to peak. PICO summary and expert commentary.